Pharmaceutical compositions for the treatment of movement disorders

• US 8,629,105 B2
• Filed: 12/23/2003
• Issued: 01/14/2014
• Est. Priority Date: 02/06/2003
• Status: Active Grant

• Current Assignee: Sarah Herzog Memorial Hospital Ezrat Nashim Association
• Original Assignee: Sarah Herzog Memorial Hospital Ezrat Nashim Association
• Inventors: Heresco-Levy, Uriel, Javitt, Daniel C.
• Primary Examiner(s): Gembeh, Shirley V
• Application Number:
  US10/744,452
• Publication Number:
  US 20040157926A1
• Time in Patent Office: 3,675 Days
• Field of Search: 514/8, 514/12, 514/561
• US Class Current: 514/8
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/42 Oxazoles
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 13/06 Anti-spasmodics
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs

Abstract

The invention provides a pharmaceutical composition, medical food, dietary supplement or micronutrient for the treatment of a movement disorder comprising an NMDAR agonist or partial agonist as active ingredient therein in combination with a pharmaceutically acceptable carrier.

Claims

1. A method for the treatment of dyskinetic symptoms in a patient with a movement disorder, comprising:

identifying a population of patients based upon said patients having at least one movement disorder selected from the group consisting of Huntington'"'"'s chorea, Wilson disease, Tourette'"'"'s disease, tic disorders, obsessive-compulsive disorder, akathisia, and dyskinesia, and selecting said patient from the population of patients;

administering to said patient a therapeutically effective amount of an agonist of the glycine-site of an N-methyl-D-aspartate (NMDA) receptor, wherein said agonist is selected from the group consisting of glycine, d-serine, a glycine uptake_inhibitor, a d-serine uptake inhibitor and combinations thereof, so as to alleviate said symptoms,

wherein glycine is used at a dose of between 15 mg and 150 g per day.

2. The method of claim 1 in which NMDAR agonists are administered at a dose sufficient to augment NMDAR mediated neurotransmission.

3. The method of claim 1, further comprising the step of administering to said patient medications known to be effective in treatment of movement disorders selected from the group consisting of dopaminergic agents, anticholinergics, adenosine modulators and combinations thereof.

4. The method of claim 1, wherein said dyskinesia is tardive dyskinesia.

5. The method of claim 1, further comprising the step of administering to said patient a therapeutically effective amount of sarcosine.

6. The method of claim 1, wherein said movement disorder is selected from the group consisting of Huntington'"'"'s chorea, Tourette'"'"'s disease, tic disorders, and obsessive-compulsive disorder.

8. The method of claim 3, wherein said dopaminergic agents comprise L-dopa.

7. A method for the treatment of dyskinetic symptoms in a patient with a movement disorder, comprising:

identifying a population of patients based upon said patients having at least one movement disorder selected from the group consisting of Huntington'"'"'s chorea, Wilson disease, Tourette'"'"'s disease, tic disorders, obsessive-compulsive disorder, akathisia, and dyskinesia, and selecting said patient from the population of patients;

administering to said patient a therapeutically effective amount of an agonist of the glycine-site of an N-methyl-D-aspartate (NMDA) receptor, wherein said agonist is selected from the group consisting of glycine, d-serine, a glycine uptake inhibitor, a d-serine uptake inhibitor and combinations thereof, so as to alleviate said symptoms,

wherein d-serine is used at a dose of 250 mg-20 g per day.

9. The method of claim 7, wherein said movement disorder is selected from the group consisting of Huntington'"'"'s chorea, Tourette'"'"'s disease, tic disorders, and obsessive-compulsive disorder.